An International, Multicenter, Randomized, Double-blind, Adaptive Placebo-controlled Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe SARS-CoV-2 Infection (COVID-19)

Samsonov et al., NCT04380519, NCT04380519, Jan 2022
Mortality -135% improvement lower risk ← → higher risk Improvement 2+ points 0% Improvement 1+ points 3% Goflikicept  Samsonov et al.  LATE TREATMENT RCT Is late treatment with goflikicept beneficial for COVID-19? Double-blind RCT 248 patients in Russia Higher mortality with goflikicept (not stat. sig., p=0.066) c19early.org Samsonov et al., NCT04380519, January 2022 0 0.5 1 1.5 2+ RR
RCT 248 hospitalized patients showing higher mortality (p=0.07) with goflikicept (RPH-104).
Important missing comments or errors? Let us know.
Study covers olokizumab and goflikicept.
risk of death, 135.2% higher, RR 2.35, p = 0.07, treatment 14 of 123 (11.4%), control 6 of 124 (4.8%), day 29.
risk of no improvement 2+ points, no change, RR 1.00, p = 1.00, treatment 30 of 124 (24.2%), control 30 of 124 (24.2%), day 29.
risk of no improvement 1+ points, 2.7% lower, RR 0.97, p = 1.00, treatment 36 of 124 (29.0%), control 37 of 124 (29.8%), NNT 124, day 29.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Samsonov et al., 24 Jan 2022, Double Blind Randomized Controlled Trial, placebo-controlled, Russia, preprint, 1 author, trial NCT04380519 (history). Contact: sa.grishin@rpharm.ru.
$0 $500 $1,000+ Efficacy vs. cost for COVID-19 treatment protocols c19early.org November 2025 Russia United Kingdom USA Pakistan Argentina Vietnam Peru Philippines Spain Brazil Italy France Japan China Uzbekistan Nepal Ethiopia Iran Ghana Mexico South Korea Germany Bangladesh Saudi Arabia Algeria Morocco Yemen Poland India DR Congo Madagascar Thailand Uganda Venezuela Nigeria Egypt Bolivia Taiwan Zambia Fiji Bosnia-Herzegovina Ukraine Côte d'Ivoire Bulgaria Greece Slovakia Singapore Iceland New Zealand Czechia Mongolia Israel Trinidad and Tobago Hong Kong North Macedonia Belarus Qatar Panama Serbia CAR Russia favored low-cost treatments.The average efficacy of treatments was very low.Low-cost treatments improve early treatment, andprovide complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
$0 $500 $1,000+ Efficacy vs. cost for COVID-19treatment protocols worldwide c19early.org November 2025 Russia United Kingdom USA Pakistan Argentina Vietnam Peru Philippines Spain Brazil Italy France Japan China Uzbekistan Nepal Ethiopia Iran Ghana Mexico South Korea Germany Bangladesh Saudi Arabia Algeria Morocco Yemen Poland India DR Congo Madagascar Thailand Uganda Venezuela Nigeria Egypt Bolivia Taiwan Zambia Fiji Ukraine Côte d'Ivoire Eritrea Bulgaria Greece Slovakia Singapore New Zealand Malawi Czechia Mongolia Israel Trinidad and Tobago North Macedonia Belarus Qatar Panama Serbia Syria Russia favored low-cost treatments.The average efficacy was very low.Low-cost protocols improve early treatment,and add complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 200,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0